30
|
Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, Cheson BD, Shepherd LE, Advani RH, Connors JM, Kahl BS, Gordon LI, Horning SJ, Steidl C, Gascoyne RD. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol 2013; 31:692-700. [PMID: 23182984 PMCID: PMC3574267 DOI: 10.1200/jco.2012.43.4589] [Citation(s) in RCA: 140] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Our aim was to reliably identify patients with advanced-stage classical Hodgkin lymphoma (cHL) at increased risk of death by developing a robust predictor of overall survival (OS) using gene expression measured in routinely available formalin-fixed paraffin-embedded tissue (FFPET). METHODS Expression levels of 259 genes, including those previously reported to be associated with outcome in cHL, were determined by digital expression profiling of pretreatment FFPET biopsies from 290 patients enrolled onto the E2496 Intergroup trial comparing doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and Stanford V regimens in locally extensive and advanced-stage cHL. A model for OS separating patients into low- and high-risk groups was produced using penalized Cox regression. The model was tested in an independent cohort of 78 patients enriched for treatment failure but otherwise similar to patients in a population-based registry of patients treated with ABVD. Weighted analysis methods generated unbiased estimates of predictor performance in the population-based registry. RESULTS A 23-gene outcome predictor was generated. The model identified a population at increased risk of death in the validation cohort. There was a 29% absolute difference in 5-year OS between the high- and low-risk groups (63% v 92%, respectively; log-rank P < .001; hazard ratio, 6.7; 95% CI, 2.6 to 17.4). The predictor was superior to the International Prognostic Score and CD68 immunohistochemistry in multivariate analyses. CONCLUSION A gene expression-based predictor, developed in and applicable to routinely available FFPET biopsies, identifies patients with advanced-stage cHL at increased risk of death when treated with standard-intensity up-front regimens.
Collapse
Affiliation(s)
- David W. Scott
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Fong Chun Chan
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Fangxin Hong
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Sanja Rogic
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - King L. Tan
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Barbara Meissner
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Susana Ben-Neriah
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Merrill Boyle
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Robert Kridel
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Adele Telenius
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Bruce W. Woolcock
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Pedro Farinha
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Richard I. Fisher
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Lisa M. Rimsza
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Nancy L. Bartlett
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Bruce D. Cheson
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Lois E. Shepherd
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Ranjana H. Advani
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Joseph M. Connors
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Brad S. Kahl
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Leo I. Gordon
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Sandra J. Horning
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Christian Steidl
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| | - Randy D. Gascoyne
- David W. Scott, Fong Chun Chan, King L. Tan, Barbara Meissner, Susana Ben-Neriah, Merrill Boyle, Robert Kridel, Adele Telenius, Bruce W. Woolcock, Joseph M. Connors, Christian Steidl, and Randy D. Gascoyne, Centre for Lymphoid Cancer, BC Cancer Agency; Sanja Rogic, Centre for High-Throughput Biology, University of British Columbia, Vancouver, British Columbia; Lois E. Shepherd, National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada; Fangxin Hong, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA; Richard I. Fisher, James P. Wilmot Cancer Centre, University of Rochester, Rochester, NY; Lisa M. Rimsza, University of Arizona, Tucson, AZ; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Ranjana H. Advani, Stanford University, Stanford; Sandra J. Horning, Genentech, South San Francisco, CA; Brad S. Kahl, University of Wisconsin, Madison, WI; Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; and Pedro Farinha, Centro Hospitalar Lisboa Central, Lisbon, Portugal
| |
Collapse
|